How many would you like? http://xnxxxxxxxx.in.net/ japanese xxx Pharmaceutical turnover edged up 1% to $7.89 billion, hit by a 14% decline in sales of the blood pressure lowerer Diovan (valsartan) to $835 million, due to generic competition in Europe. Although off-patent in the USA, Novartis is still benefitting from the fact that the Food and Drug Administration has yet to approve any competitor for Diovan monotherapy.